Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Chuikyo Approves 8 Drugs for Inclusion in NHI Price List
June 5, 2006
- Suzuken: Addition of Astis Boosts Sales
June 5, 2006
- Chuikyo Approves NHI Price Listing of Nicotine Patch
June 5, 2006
- Alfresa HD: Sales Exceed \1.4 Trillion
June 5, 2006
- New Dosage Forms of Itraconazole, Moxifloxacin Recommended for Approval
June 5, 2006
- Toho: Solid Growth in Sales, Profits
June 5, 2006
- Avonex, Baraclude Recommended for Approval
June 5, 2006
- Hokuyaku, Takeyama to Integrate Business in September
June 5, 2006
- Mr Niwa Offers 8 Proposals for Social Security Reform
June 5, 2006
- Risk from TGN1412 Could Have Been Predicted: Cambridge Professor
June 5, 2006
- Huntingdon Life Sciences to Expand Japanese Business: Mr Cass
June 5, 2006
- Korosho to Develop Individualized Treatment for Esophageal Cancer
June 5, 2006
- REGULATORY NEWS IN BRIEF
June 5, 2006
- New Requirement Related to IRBs May Delay Clinical Trials: Medical Associations
June 5, 2006
- CMIC Allies with KineMed to Add Value to Aborted Compounds
June 5, 2006
- R&D NEWS IN BRIEF
June 5, 2006
- Sales Force Effectiveness Japan
June 5, 2006
- Vesicare Drug of Choice for OAB: Prof. Yamaguchi
June 5, 2006
- INTERPHEX JAPAN
June 5, 2006
- Early Discovery, Continuous Treatment with Anticoagulants Important for Cerebral Infarction
June 5, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…